Organization (Hospital)
New York Presbyterian Brooklyn Methodist Hospital
ClinicalTrials.gov lists New York Presbyterian Brooklyn Methodist Hospital as lead sponsor of 16 trials. It has 6 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo NewYork-Presbyterian Hospital, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers New York Presbyterian Brooklyn Methodist Hospital: 16 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (36)
Shown in this order: most trials first (counted at this company's own legal-entity record, not the consolidated group).
| Disease area | Trials |
|---|---|
| Prostatic Neoplasms | 2 |
| Shock, Septic | 2 |
| Agnosia | 2 |
| Inflammation | 2 |
| Sepsis | 2 |
Showing 5 of 36 disease areas.
Trials by start year as sponsor or collaborator (16)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 2 |
| 2024 | 1 |
| 2021 | 1 |
| 2020 | 1 |
| 2019 | 2 |
| 2018 | 1 |
| 2017 | 1 |
| 2016 | 1 |
| 2014 | 1 |
Showing 10 of 16 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (6)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| IV Solution | 1 |
| FUROSEMIDE | 1 |
| Bupivicaine | 1 |
| Vitamin C | 1 |
| Lactulose | 1 |
Showing 5 of 6 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 1 of 2 hit target (n=2) | 1 of 2 on time (n=2) |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 3 |
CLIA clinical laboratory certificates (3)
Shown in this order: active first, then certificate type.
| Lab | Certificate | Status |
|---|---|---|
| NEW YORK METHODIST HOSPITAL | Certificate of waiver | Terminated |
| NEW YORK METHODIST HOSPITAL | Certificate of waiver | Terminated |
| NEW YORK METHODIST HOSPITAL | Certificate of waiver | Terminated |
Biomarker capability evidence (14)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| FLNB | Trial sponsor | Primary endpoint in a Phase 3 trial |
| NXF1 | Trial sponsor | Primary endpoint in a Phase 3 trial |
| CD4 | Trial sponsor | Named in trial exclusion criteria |
| G6PD | Trial sponsor | Named in trial exclusion criteria |
| H6PD | Trial sponsor | Named in trial exclusion criteria |
Showing 5 of 14 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and organization relationships.
Counted at group level under NewYork–Presbyterian Hospital: journals published in, us granted patents, latest dated events, and biomarkers this organization publishes on.